p63 expression as a new prognostic marker in Mrkel cell carcinoma

Sofia Asioli, Alberto Righi, Marco Volante, Vincenzo Eusebi, Gianni Bussolati

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

BACKGROUND. Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin tumor, mostly affecting elderly individuals. The histogenesis of this rare tumor as well as its prognostic criteria are a matter of dispute. METHODS. An immunohistochemical analysis of markers of proliferation (Ki-67/MIB-1), neuroendocrine differentiation (chromogranin A and synaptophysin), and basal cell differentiation (p63) was performed in a series of 47 cases of MCC. The significance of pathologic data and of immunoreactivity with different markers was evaluated using the chi-square test. Survival curves were calculated using the Kaplan-Meyer method. The survival difference was estimated using the Wilcoxon or Mantel-Cox test. RESULTS. Immunohistochemical evidence of neuroendocrine differentiation and immunopositivity for cytokeratin 20 were observed in all cases, whereas positivity for p63 was detected in approximately half of the cases (25 of 47 cases; 53.2%). Cases that were positive for p63 demonstrated a more aggressive clinical course than those that were negative (Z value of 2.93; P = .0003; hazards ratio of 22.22). CONCLUSIONS. Data from the current study indicate that p63 expression is associated with a worse prognosis in patients with MCC and represents a new independent marker of clinical evolution.

Original languageEnglish
Pages (from-to)640-647
Number of pages8
JournalCancer
Volume110
Issue number3
DOIs
Publication statusPublished - Aug 1 2007

Fingerprint

Merkel Cell Carcinoma
Carcinoma
Keratin-20
Chromogranin A
Synaptophysin
Dissent and Disputes
Survival
Neuroendocrine Tumors
Chi-Square Distribution
Cell Differentiation
Biomarkers
Skin
Neoplasms

Keywords

  • Ki-67/MIB-1
  • Merkel cell carcinoma
  • p53
  • p63
  • Prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Asioli, S., Righi, A., Volante, M., Eusebi, V., & Bussolati, G. (2007). p63 expression as a new prognostic marker in Mrkel cell carcinoma. Cancer, 110(3), 640-647. https://doi.org/10.1002/cncr.22828

p63 expression as a new prognostic marker in Mrkel cell carcinoma. / Asioli, Sofia; Righi, Alberto; Volante, Marco; Eusebi, Vincenzo; Bussolati, Gianni.

In: Cancer, Vol. 110, No. 3, 01.08.2007, p. 640-647.

Research output: Contribution to journalArticle

Asioli, S, Righi, A, Volante, M, Eusebi, V & Bussolati, G 2007, 'p63 expression as a new prognostic marker in Mrkel cell carcinoma', Cancer, vol. 110, no. 3, pp. 640-647. https://doi.org/10.1002/cncr.22828
Asioli, Sofia ; Righi, Alberto ; Volante, Marco ; Eusebi, Vincenzo ; Bussolati, Gianni. / p63 expression as a new prognostic marker in Mrkel cell carcinoma. In: Cancer. 2007 ; Vol. 110, No. 3. pp. 640-647.
@article{d2f911b3fbb24c3f9721d4a96d48f7e9,
title = "p63 expression as a new prognostic marker in Mrkel cell carcinoma",
abstract = "BACKGROUND. Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin tumor, mostly affecting elderly individuals. The histogenesis of this rare tumor as well as its prognostic criteria are a matter of dispute. METHODS. An immunohistochemical analysis of markers of proliferation (Ki-67/MIB-1), neuroendocrine differentiation (chromogranin A and synaptophysin), and basal cell differentiation (p63) was performed in a series of 47 cases of MCC. The significance of pathologic data and of immunoreactivity with different markers was evaluated using the chi-square test. Survival curves were calculated using the Kaplan-Meyer method. The survival difference was estimated using the Wilcoxon or Mantel-Cox test. RESULTS. Immunohistochemical evidence of neuroendocrine differentiation and immunopositivity for cytokeratin 20 were observed in all cases, whereas positivity for p63 was detected in approximately half of the cases (25 of 47 cases; 53.2{\%}). Cases that were positive for p63 demonstrated a more aggressive clinical course than those that were negative (Z value of 2.93; P = .0003; hazards ratio of 22.22). CONCLUSIONS. Data from the current study indicate that p63 expression is associated with a worse prognosis in patients with MCC and represents a new independent marker of clinical evolution.",
keywords = "Ki-67/MIB-1, Merkel cell carcinoma, p53, p63, Prognosis",
author = "Sofia Asioli and Alberto Righi and Marco Volante and Vincenzo Eusebi and Gianni Bussolati",
year = "2007",
month = "8",
day = "1",
doi = "10.1002/cncr.22828",
language = "English",
volume = "110",
pages = "640--647",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - p63 expression as a new prognostic marker in Mrkel cell carcinoma

AU - Asioli, Sofia

AU - Righi, Alberto

AU - Volante, Marco

AU - Eusebi, Vincenzo

AU - Bussolati, Gianni

PY - 2007/8/1

Y1 - 2007/8/1

N2 - BACKGROUND. Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin tumor, mostly affecting elderly individuals. The histogenesis of this rare tumor as well as its prognostic criteria are a matter of dispute. METHODS. An immunohistochemical analysis of markers of proliferation (Ki-67/MIB-1), neuroendocrine differentiation (chromogranin A and synaptophysin), and basal cell differentiation (p63) was performed in a series of 47 cases of MCC. The significance of pathologic data and of immunoreactivity with different markers was evaluated using the chi-square test. Survival curves were calculated using the Kaplan-Meyer method. The survival difference was estimated using the Wilcoxon or Mantel-Cox test. RESULTS. Immunohistochemical evidence of neuroendocrine differentiation and immunopositivity for cytokeratin 20 were observed in all cases, whereas positivity for p63 was detected in approximately half of the cases (25 of 47 cases; 53.2%). Cases that were positive for p63 demonstrated a more aggressive clinical course than those that were negative (Z value of 2.93; P = .0003; hazards ratio of 22.22). CONCLUSIONS. Data from the current study indicate that p63 expression is associated with a worse prognosis in patients with MCC and represents a new independent marker of clinical evolution.

AB - BACKGROUND. Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin tumor, mostly affecting elderly individuals. The histogenesis of this rare tumor as well as its prognostic criteria are a matter of dispute. METHODS. An immunohistochemical analysis of markers of proliferation (Ki-67/MIB-1), neuroendocrine differentiation (chromogranin A and synaptophysin), and basal cell differentiation (p63) was performed in a series of 47 cases of MCC. The significance of pathologic data and of immunoreactivity with different markers was evaluated using the chi-square test. Survival curves were calculated using the Kaplan-Meyer method. The survival difference was estimated using the Wilcoxon or Mantel-Cox test. RESULTS. Immunohistochemical evidence of neuroendocrine differentiation and immunopositivity for cytokeratin 20 were observed in all cases, whereas positivity for p63 was detected in approximately half of the cases (25 of 47 cases; 53.2%). Cases that were positive for p63 demonstrated a more aggressive clinical course than those that were negative (Z value of 2.93; P = .0003; hazards ratio of 22.22). CONCLUSIONS. Data from the current study indicate that p63 expression is associated with a worse prognosis in patients with MCC and represents a new independent marker of clinical evolution.

KW - Ki-67/MIB-1

KW - Merkel cell carcinoma

KW - p53

KW - p63

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=34547104216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547104216&partnerID=8YFLogxK

U2 - 10.1002/cncr.22828

DO - 10.1002/cncr.22828

M3 - Article

VL - 110

SP - 640

EP - 647

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -